Brief: Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (Calcium, Magnesium, Potassium, And Sodium Oxybates) Oral Solution Treatment Outcomes In Narcolepsy At Sleep 2025
09/06/2025 23:00
Jazz Pharmaceuticals PLC JAZZ.O: JAZZ PHARMACEUTICALS PRESENTS LATE-BREAKING PHASE 4 DATA SHOWCASING XYWAV® (CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES) ORAL SOLUTION TREATMENT OUTCOMES IN NARCOLEPSY AT SLEEP 2025 Source text: ID:nPn5rNf2Ya Further company coverage: JAZZ.O
Recent news on Jazz Pharmaceuticals
See all newsBrief: Jazz Pharmaceuticals Enters Amendment No. 4 To Credit Agreement On Sept 23, 2026
U.S. STOCKS ON THE MOVE-BWX Technologies, Synopsys,Burlington Stores
U.S. STOCKS ON THE MOVE-Jazz Pharmaceuticals, Celularity, Infleqtion
Jazz Pharma dips after upsized $1.1 bln convertible offering
Brief: Jazz Pharmaceuticals Announces Private Offering Of $1.0 Billion Of Exchangeable Senior Notes Due 2032